| Literature DB >> 34797002 |
Chiara Veneroni1, Pasquale Pio Pompilio1, Kjell Alving2, Christer Janson3, Leif Nordang4, Raffaele Dellacà1, Henrik Johansson5,6, Andrei Malinovschi6.
Abstract
BACKGROUND: Self-reported exercise-induced dyspnea (EID) is common among adolescents. Possible underlying pathologies are exercise-induced bronchoconstriction (EIB) and laryngeal obstruction (EILO). The forced oscillation technique (FOT) may evaluate exercise-induced changes in airway caliber. AIM: To investigate in adolescents the relationship between EID, EIB (post-exercise fall in forced expiratory volume in 1s (FEV1 )≥10%), EILO, and post-exercise challenge changes in FOT parameters.Entities:
Keywords: exercise-induced bronchoconstriction; exercise-induced dyspnea; exercise-induced laryngeal obstruction; forced oscillation technique
Mesh:
Year: 2021 PMID: 34797002 PMCID: PMC9299675 DOI: 10.1111/pai.13702
Source DB: PubMed Journal: Pediatr Allergy Immunol ISSN: 0905-6157 Impact factor: 5.464
Studied population
| nonEID‐nonEIB | EID‐nonEIB | EIB | All | |
|---|---|---|---|---|
| n | 40 | 56 | 47 | 143 |
| Age [y] | 14 (14; 15) | 14 (14; 15) | 14 (14; 15) | 14 (14;15) |
| Girls | 22 (55) | 29 (52) | 35 (74) | 86 (60) |
| Height [cm] | 171 (163; 177) | 167 (162; 173) | 166 (162; 173) | 168 (163; 175) |
| Weight [kg] | 57 (52; 69) | 57 (51; 66) | 58 (55; 64) | 58 (53; 67) |
| Atopy (IgE≥0.35 kU/L) | 17 (42) | 27 (59) | 19 (40) | 63 (44) |
| Rhinitis | 11 (27) | 30 (54) | 17 (36) | 58 (41) |
| Ever asthma | 2 (5) | 19 (34)* | 21(45)* | 42 (29) |
| ICS | 3 (7) | 8 (14) | 12 (25) | 23 (16) |
| SABA | 2 (5) | 22 (39)* | 18 (38)* | 42 (29) |
| LTRA | 0 (0) | 3 (5) | 2 (4) | 5 (3) |
| EILO | 2 (5) | 3 (5) | 4 (10) | 9 (7) |
| ECP [mgl] | 8.7 (5.7; 13.9) | 10.9 (7.0; 16.9) | 14.9 (8.9; 23.3)* | 11.6 (7.1; 17.0) |
| FeNO [ppb] | 13.2 (9.5; 18.9) | 11.2 (8.5; 17.0) | 14.4 (10.7; 30.8)^ | 13.1 (9.5; 19.1) |
| FVC (%pred) | 97.0 (89.6; 104.3) | 93.6 (88.5; 105.8) | 92.8 (84.1; 98.8) | 93.7 (86.2;103.2) |
| FEV1 (% pred) | 95.6 (87.4; 98.9) | 96.1 (85.9; 99.0) | 90.4 (83.6; 95.5) | 93.6 (85.9; 98.3) |
| FEV1/FVC | 0.88 (0.84; 0.92) | 0.89 (0.84; 0.92) | 0.86 (0.82; 0.94) | 0.88 (0.83; 0.93) |
| R5 [cmH2O*s/L] | 3.5 (3.2; 3.7) | 3.6 (3.4; 4.4) | 3.8 (3.3; 4.3) | 3.6 (3.3; 4.3) |
| z_score R5 | −0.07 (−0.25; 0.16) | 0.04 (−0.10; 0.26) | 0.09 (−0.14;0.30) | 0.02 (−0.14;0.27) |
| R5,insp [cmH2O*s/L] | 2.9 (2.6; 3.3) | 3.2 (2.8; 3.7)* | 3.3 (2.9; 3.6)* | 3.1 (2.8;3.5) |
| R5,esp [cmH2O*s/L] | 3.8 (3.5; 4.3) | 4.1 (3.7; 5.1) | 4.1 (3.6; 4.9) | 4.0 (3.6; 4.8) |
| X5 [cmH2O*s/L] | −0.9 (−1.2; −0.7) | −1.1 (−1.4; −0.8) | −1.0 (−1.4; −0.8) | −1.0 (−1.4; −0.75) |
| z_score X5 | 0.02 (−0.30;0.50) | 0.16 (−0.33;0.56) | 0.15 (−0.24;0.50) | 0.11 (−0.30;0.51) |
| X5,insp [cmH2O*s/L] | −1.2 (−1.5; −0.9) | −1.4 (−1.7; −1.0) | −1.4 (−1.8; −1.0) | −1.4 (−1.6; −1.0) |
| X5,esp [cmH2O*s/L] | −0.7 (−0.9; −0.5) | −0.9 (−1.2; −0.6) | −0.8 (−1.1; −0.6) | −0.8 (−1.1; −0.6) |
| |Z5| [cmH2O*s/L] | 3.6 (3.3; 3.9) | 3.8 (3.5; 4.6) | 3.9 (3.5; 4.5) | 3.8 (3.4; 4.5) |
| |Z5,insp| [cmH2O*s/L] | 3.2 (2.7; 3.7) | 3.5 (3.0; 4.0) * | 3.7 (3.1; 4.0) * | 3.4 (3.1;3.8) |
| |Z5,esp| [cmH2O*s/L] | 4.0 (3.8; 4.7) | 4.3 (3.9; 5.4) | 4.4 (3.9; 5.2) | 4.2 (3.8; 5.2) |
| R5‐R19 [cmH2O*s/L] | 0.03 (−0.16; 0.27) | 0.11 (−0.05;0.30) | 0.20 (−0.02;0.35) | 0.12 (−0.06;0.31) |
Data are reported as median (IQR) or number (percentage). ICS, SABA, and LTRA usage in the previous 3 months was self‐reported.
Abbreviations: |Z5,esp|, expiratory |Z5|; |Z5,insp|, inspiratory |Z5|; |Z5|, impedance modulus at 5 Hz; ECP, eosinophil cationic protein; EIB, exercise‐induced bronchoconstriction; EID, exercise‐induced dyspnea; EILO, exercise‐induced laryngeal obstruction; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonists; R5, respiratory resistance at 5 Hz; R5,esp, expiratory R5; R5,insp, inspiratory R5; R5‐R19, difference between R5 and the respiratory resistance at 19 Hz; SABA, short‐acting beta agonists; X5, respiratory reactance at 5 Hz; X5,esp, expiratory X5; X5,insp, inspiratory X5.
tested only on 123 subjects (37 nonEID‐nonEIB, 45 EID‐nonEIB, and 41 EIB).
p<0.05 compared to nonEID‐nonEIB; ^ p<0.05 compared to EID‐nonEIB.
FIGURE 1Post‐exercise changes from baseline in inspiratory resistance (R5,insp), reactance (X5,insp), impedance modulus (|Z5,insp|), and forced expiratory volume in 1s (FEV1). EID, exercise‐induced dyspnea; EIB, exercise‐induced bronchoconstriction
FIGURE 2Relationship between forced expiratory volume in 1 s (FEV1) fall and maximal change after exercise in the inspiratory impedance modulus (Δ|Z5,insp|) in subjects with (EID, close circles) and without (nonEID, open circles) exercise‐induced dyspnea. Dashed lines represent the thresholds for positive responses to exercise. Four groups are identified groups according to their response to the exercise challenge: subjects that responded to exercise for both FEV1 and FOT (FEV1&FOTresponders), only FEV1 (onlyFEV1responders), only FOT (onlyFOTresponders), and non‐responders. Linear regression (r 2 = .38, p < .001) is also shown (dark gray line)
FIGURE 3Venn diagram depicting the association between exercise‐induced dyspnea (EID), exercise‐induced bronchoconstriction (EIB), and exercise‐induced changes in oscillometry (FOT responders) in adolescents
FOT and FEV1 responders to exercise test
| Non‐responders | onlyFOTresponders | onlyFEV1responders | FEV1&FOTresponders | |
|---|---|---|---|---|
|
FEV1 fall<10% Δ|Z5,insp| <1.15 cmH2O |
FEV1 fall <10% Δ|Z5,insp|>1.15 cmH2O |
FEV1 fall >10% Δ|Z5,insp|<1.15 cmH2O |
FEV1 fall >10% Δ|Z5,insp|>1.15 cmH2O | |
| n | 78 | 18 | 19 | 28 |
| Age [y] | 14 (14; 15) | 14 (14; 15) | 14 (14; 15) | 14 (14; 15) |
| Girls | 46 (59) | 5 (28) | 15 (79)^ | 20 (71)^ |
| Height [cm] | 170 (163; 176) | 168 (160; 173) | 167 (161; 174) | 166 (163; 171) |
| Weight [kg] | 57 (52; 67) | 58 (51; 69) | 62 (53; 65) | 57 (55; 61) |
| Atopy(IgE≥0.35kU/L) | 36 (46) | 8 (44) | 5 (26) | 14 (50) |
| Rhinitis | 33 (42) | 8 (44) | 4 (21) | 13 (46) |
| Ever asthma | 18 (23) | 3 (17) | 5 (26) | 16 (57)* |
| ICS | 10 (13) | 1 (6) | 3 (16) | 9 (32) |
| SABA | 19 (24) | 5 (28) | 7 (37) | 11 (39) |
| LTRA | 1 (1) | 0 (0) | 1 (5) | 2 (7) |
| EILO | 3 (4) | 2 (11) | 1 (5) | 3 (11) |
| EID | 45 (58) | 11 (61) | 16 (84) | 25 (89)* |
| ECP [mgl] | 9.8 (6.1; 15.9) | 12.2 (5.5; 15.9) | 11.6 (7.5; 17.5) | 15.8 (11.1; 28.7)* |
| FeNO [ppb] | 11.4 (8.7; 17.3) | 15.2 (10.2; 22.3) | 12.8 (9.2; 16.3) | 19.9 (12.8; 38.4)* |
| FVC (%pred) | 93.8 (86.4; 102.3) | 102.1 (93.7; 109.4) | 89.9 (83.3; 99.0)^ | 93.3 (85.1; 98.3) |
| FEV1 (%pred) | 96.0 (85.9; 99.1) | 95.9 (92.2; 98.5) | 93.3 (84.3; 97.0) | 89.5 (82.1; 94.6) |
| FEV1/FVC | 0.89 (0.85; 0.93) | 0.85 (0.78; 0.89) | 0.92 (0.84; 0.98)^ | 0.84 (0.82; 0.92) |
| R5 [cmH2O*s/L] | 3.6 (3.3; 4.3) | 3.6 (3.3; 4.3) | 3.8 (3.4; 4.1) | 3.8 (3.2; 4.4) |
| z_score R5 | 0.02 (−0.14;0.29) | −0.03 (−0.09;0.13) | 0.11 (−0.12;0.34) | 0.06 (−0.16;0.29) |
| R5,insp [cmH2O*s/L] | 3.0 (2.7; 3.5) | 3.2 (2.8; 3.5) | 3.3 (3.0;3.5) | 3.3 (2.9; 3.8) |
| R5,esp [cmH2O*s/L] | 3.9 (3.6;4.6) | 4.0 (3.6;5.1) | 4.1 (3.8; 4.6) | 4.1 (3.5; 5.0) |
| X5 [cmH2O*s/L] | −1.1 (−1.4; −0.7) | −0.9 (−1.1; −0.8) | −1.0 (−1.4; −0.8) | −1.1 (−1.4; −0.8) |
| z_score X5 | 0.16 (−0.32;0.65) | −0.18 (−0.32;0.18) | 0.25 (−0.28;0.38) | 0.05 (−0.23;0.82) |
| X5,insp [cmH2O*s/L] | −1.3 (−1.7; −0.9) | −1.3 (−1.5; −1.1) | −1.5 (−1.8; −1.0) | −1.4 (−1.6; −1.0) |
| X5,esp [cmH2O*s/L] | −0.8 (−1.1; −0.5) | −0.7 (−0.9; −0.6) | −0.8 (−1.0; −0.4) | −0.8 (−1.2; −0.6) |
| |Z5| [cmH2O*s/L] | 3.7 (3.4; 4.5) | 3.7 (3.4; 4.4) | 4.0 (3.5; 4.3) | 3.8 (3.4; 4.6) |
| |Z5,insp| [cmH2O*s/L] | 3.4 (2.9; 3.8) | 3.5 (2.9; 3.9) | 3.7 (3.2; 3.8) | 3.6 (3.1; 4.1) |
| |Z5,esp| [cmH2O*s/L] | 4.2 (3.8; 5.0) | 4.1 (3.8; 5.5) | 4.5 (4.0; 5.0) | 4.3 (3.8; 5.3) |
| R5‐R19 [cmH2O*s/L] | 0.12 (−0.07;0.30) | 0.02 (−0.17;0.17) | 0.14 (−0.02;0.36) | 0.21(−0.02;0.33) |
Data are reported as median (IQR) or number (percentage). ICS, SABA, and LTRA usage in the previous 3 months was self‐reported.
Abbreviations: |Z5,esp|, expiratory |Z5|; |Z5,insp|, inspiratory |Z5|; |Z5|, impedance modulus at 5 Hz; ECP, eosinophil cationic protein; EID, exercise‐induced dyspnea; EILO, exercise‐induced laryngeal obstruction; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonists; R5, respiratory resistance at 5 Hz; R5,esp, expiratory R5; R5,insp, inspiratory R5; X5,insp, inspiratory X5; R5‐R19, difference between R5 and the respiratory resistance at 19 Hz; SABA, short‐acting beta agonists; X5, respiratory reactance at 5 Hz; X5,esp, expiratory X5; Δ|Z5,insp|, changes in the modulus of the inspiratory impedance after exercise.
tested only on 123 subjects (67 non‐responders, 15 onlyFOTresponders, 15 onlyFEV1responders, and 26 FEV1&FOTresponders).
p < .05 compared to FEV1&FOTresponders; ^p < .05 compared to onlyFOTresponders.
FOT parameters and EILO
| nonEID‐nonEIB‐nonEILO | EILO | |
|---|---|---|
| n | 35 | 9 |
| Age [y] | 14 (14; 15) | 14 (14;15) |
| Girls | 20 (57) | 7 (78) |
| Height [cm] | 171 (163; 177) | 167 (163; 174) |
| Weight [kg] | 57 (51; 68) | 57 (53; 76) |
| Atopy (IgE≥0.35kU/L) | 15 (43) | 2 (22) |
| Rhinitis | 11 (32) | 1 (11) |
| Ever asthma | 2 (6) | 3 (33) |
| ICS | 3 (9) | 1 (11) |
| SABA | 2 (6) | 2 (22) |
| LTRA | 0 (0) | 1 (11) |
| ECP [mgl] | 9.2 (5.6; 14.0) | 7.9 (4.0; 34.3) |
| FeNO [ppb] | 13.2 (9.6; 18.8) | 14.4 (8.2; 19.9) |
| FVC (%pred) | 94.9 (86.9; 104.4) | 98.4 (89.7; 102.6) |
| FEV1 (% pred) | 95.2 (86.8; 99.2) | 96.0 (89.9; 98.6) |
| FEV1/FVC | 0.89 (0.84; 0.93) | 0.90 (0.85; 0.93) |
| R5 [cmH2O*s/L] | 3.5 (3.2;3.7) | 3.5 (3.1;4.3) |
| z_score R5 | 0.006 (−0.259; 0.269) | −0.021 (−0.087; 0.141) |
| R5,insp [cmH2O*s/L] | 3.0 (2.6;3.3) | 3.0 (2.8;3.5) |
| R5,esp [cmH2O*s/L] | 3.9 (3.6;4.3) | 4.2 (3.7;4.9) |
| X5 [cmH2O*s/L] | −0.9 (−1.2; −0.7) | −1.2 (−1.5; −0.8) |
| z_score X5 | 0.12 (−0.27; 0.57) | 0.46 (0.13; 0.74) |
| X5,insp [cmH2O*s/L] | −1.3 (−1.5; −0.9) | −1.4 (−2.1; −0.9) |
| X5,esp [cmH2O*s/L] | −0.7 (−1.0; −0.5) | −0.7 (−1.1; −0.7) |
| |Z5| [cmH2O*s/L] | 3.7 (3.4;3.9) | 3.7 (3.3;4.6) |
| |Z5,insp| [cmH2O*s/L] | 3.3 (2.8;3.7) | 3.2 (3.0; 4.0) |
| |Z5,esp| [cmH2O*s/L] | 4.1 (3.8;4.7) | 4.3 (3.9;5.4) |
| R5,insp‐ R5,esp [cmH2O*s/L] | −0.9 (−1.4; −0.7) | −1.0 (−1.5;−0.9) |
| FEV1 fall | 4.3 (2.2;6.8) | 6.1 (4.1;15.1) |
| ΔR5 [cmH2O*s/L] | 0.7 (0.3; 1.0) | 1.3 (0.6;1.8) |
| Δz_score R5 | 0.4 (0.2;0.5) | 0.7 (0.2;0.9) |
| ΔR5,insp [cmH2O*s/L] | 0.6 (0.3;0.9)* | 1.2 (0.7; 1.3) |
| ΔR5,esp [cmH2O*s/L] | 0.8 (0.4;1.3) | 0.8 (0.3;2.1) |
| ΔX5 [cmH2O*s/L] | −0.3 (−0.5; −0.03) | −0.5 (−0.7; −0.3) |
| Δz_score X5 | 0.5 (0.06; 0.9) | 0.9 (0.5; 1.2) |
| ΔX5,insp [cmH2O*s/L] | −0.4 (−0.6; −0.2) | −0.7 (−0.9; −0.4) |
| ΔX5,esp [cmH2O*s/L] | −0.2 (−0.5; −0.06) | −0.5 (−0.7; −0.2) |
| Δ|Z5| [cmH2O*s/L] | 0.7 (0.2;1.0) | 1.0 (0.1;1.6) |
| Δ|Z5,insp| [cmH2O*s/L] | 0.7 (0.4;0.9) | 1.3 (0.5;1.4) |
| Δ|Z5,esp| [cmH2O*s/L] | 0.9 (0.4;1.3) | 1.0 (0.5;2.0) |
| max R5,insp‐R5,esp [cmH2O*s/L] | −0.7 (−0.9; −0.3) | −0.7 (−0.9; −0.5) |
Data are reported as median (IQR) or number (percentage). ICS, SABA, and LTRA usage in the previous 3 months was self‐reported.
Abbreviations: |Z5,insp|, inspiratory |Z5|; |Z5,esp|, expiratory |Z5|; |Z5|, impedance modulus at 5 Hz; ECP, eosinophil cationic protein; EIB, exercise‐induced bronchoconstriction; EID, exercise‐induced dyspnea; EILO, exercise‐induced laryngeal obstruction; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonists; max R5,insp‐R5,esp, maximal post‐exercise value of R5,insp‐R5,esp; R5, respiratory resistance at 5 Hz; R5,esp, expiratory R5; R5,insp, inspiratory R5; SABA, short‐acting beta agonists; X5, respiratory reactance at 5 Hz; X5,esp, expiratory X5; X5,insp, inspiratory X5; Δ|Z5,esp|, maximal post‐exercise change in |Z5,esp|; Δ|Z5,insp|, maximal post‐exercise change in |Z5,insp|; Δ|Z5|, maximal post‐exercise change in |Z5|; ΔR5, maximal post‐exercise change in R5; ΔR5,esp=maximal post‐exercise change in R5,esp; ΔR5,insp, maximal post‐exercise change in ΔR5,insp; ΔX5, maximal post‐exercise change in X5; ΔX5,esp, maximal post‐exercise change in X5,esp; ΔX5,insp, maximal post‐exercise change in X5,insp; Δz_score R5, maximal post‐exercise change in z_score of R5; Δz_score X5= maximal post‐exercise change in z_score of X5.
tested only on 123 subjects (67 non‐responders, 15 onlyFOTresponders, 15 onlyFEV1responders, and 26 FEV1&FOTresponders).
p < .05 compared to FEV1&FOTresponders; ^p < .05 compared to onlyFOTresponders.